Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma

Authors

Institutions

Publication Details

Journal
Targeted Oncology
Published
2025-05-07
DOI
https://doi.org/10.1007/s11523-025-01149-1
Citations
5
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
8.85

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma

Yaming Su, Mahesh N. Samtani, Deeksha Vishwamitra, Jin Niu et al.
5 citations
Targeted Oncology
Multiple Myeloma Research and Treatments
8.85
article

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma

Yaming Su, Mahesh N. Samtani, Deeksha Vishwamitra, Jin Niu, Carlos Pérez Ruixo, Natalia A. Quijano Cardé, Steven Hanson, Katherine Chastain, Nahor Haddish‐Berhane, Yue Guo, Weirong Wang, Xin Miao, Liviawati S. Wu
article en
5 citations

Abstract

No abstract available for this paper.
Targeted OncologyVol. 20(4)
Johnson & Johnson (United States) (US)
Johnson and Johnson
Zero hunger
Openalex Percentile: Top 2%
Multiple Myeloma Research and Treatments
8.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.